{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:26:59Z","timestamp":1771676819066,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12185-020-02886-x","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:41:49Z","timestamp":1588009309000},"page":"422-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy"],"prefix":"10.1007","volume":"112","author":[{"given":"Kentaro","family":"Mizuhara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Meguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Aoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Sando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sumii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Urata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakazu","family":"Nishimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/MOH.0b013e328353bc7d","volume":"19","author":"M Bosch","year":"2012","unstructured":"Bosch M, Khan F, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19:324\u201335.","journal-title":"Curr Opin Hematol"},{"key":"2886_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2014.28","volume":"49","author":"Y Arai","year":"2014","unstructured":"Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, et al. Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplant. 2014;49:859\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"2886_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","volume":"41","author":"A-C Norlin","year":"2008","unstructured":"Norlin A-C, Sairafi D, Mattsson J, Ljungman P, Ringde\u2019n O, Remberger M, et al. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant. 2008;41:267\u201373.","journal-title":"Bone Marrow Transplant"},{"key":"2886_CR4","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/bmt.2013.76","volume":"48","author":"H Frangoul","year":"2013","unstructured":"Frangoul H, Min E, Wang W, Chandrasekhar R, Calder C, Evans M, et al. Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. Bone Marrow Transplant. 2013;48:1456\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2886_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.V98.2.489","volume":"98","author":"J Storek","year":"2001","unstructured":"Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood. 2001;98:489\u201391.","journal-title":"Blood"},{"key":"2886_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2008.385","volume":"43","author":"K Masjosthusmann","year":"2009","unstructured":"Masjosthusmann K, Ehlert K, Eing BR, Roth J, Koehler G, Juergens H, et al. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;43:679\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"2886_CR7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1097\/TP.0b013e318188ac0c","volume":"86","author":"V Gu\u00e9rin","year":"2008","unstructured":"Gu\u00e9rin V, Yakouben K, Lescoeur B, P\u00e9dron B, Dalle J-H, Baruchel A, et al. Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child. Transplantation. 2008;86:1322\u20133.","journal-title":"Transplantation"},{"key":"2886_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-0609.2005.00552.x","volume":"75","author":"M Nishio","year":"2005","unstructured":"Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol. 2005;75:527\u20139.","journal-title":"Eur J Haematol"},{"key":"2886_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","volume":"33","author":"S Imashuku","year":"2004","unstructured":"Imashuku S, Teramura T, Morimoto A, Naya M, Kuroda H. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant. 2004;33:129\u201330.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2886_CR10","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis RE, Travis LB, Rowlings PA, Soci\u00e9 G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208\u201316.","journal-title":"Blood"},{"key":"2886_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.bbmt.2019.02.016","volume":"25","author":"A Fujimoto","year":"2019","unstructured":"Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, et al. Risk factors and predictive scoring system For post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1441\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2886_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/TP.0b013e3182664042","volume":"94","author":"AD Petropoulou","year":"2012","unstructured":"Petropoulou AD, Porcher R, Peffautl de Laour R, Xhaard A, Weisdorf D, Ribaud P, et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2012;94:879\u201383.","journal-title":"Transplantation"},{"key":"2886_CR13","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.1998.16.3.1008","volume":"16","author":"P Mc Laughlin","year":"1998","unstructured":"Mc Laughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2835\u2013928.","journal-title":"J Clin Oncol"},{"key":"2886_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","volume":"77","author":"M Nishio","year":"2005","unstructured":"Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol. 2005;77:226\u201332.","journal-title":"Eur J Haematol"},{"key":"2886_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2141.2007.06584.x","volume":"137","author":"M Nishio","year":"2007","unstructured":"Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol. 2007;137:349\u201354.","journal-title":"Br J Haematol"},{"key":"2886_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/sj.bmt.1705463","volume":"38","author":"J Shortt","year":"2006","unstructured":"Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2006;38:433\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2886_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","volume":"35","author":"SH Lim","year":"2005","unstructured":"Lim SH, Zhang Y, Wang Z, Esler WV, Beggs D, Pruitt B, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant. 2005;35:207\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2886_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/eji.1830270835","volume":"27","author":"K Agematsu","year":"1997","unstructured":"Agematsu K, Nagumo H, Yang F, Nakazawa T, Fukushima K, et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoblobulin production. Eur J Immunol. 1997;27:2073\u20139.","journal-title":"Eur J Immunol"},{"key":"2886_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","volume":"14","author":"HT Greinix","year":"2008","unstructured":"Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lobmann I, et al. Elevated numbers of immagure\/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:208\u201319.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2886_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2008.11.024","volume":"15","author":"LJ D\u2019Orsogna","year":"2009","unstructured":"D\u2019Orsogna LJ, Wright MP, Krueger RG, McKinnon EJ, Buffery SI, et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant. 2009;15:795\u2013803.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2886_CR21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.bbmt.2010.05.004","volume":"16","author":"Z Mcver","year":"2010","unstructured":"Mcver Z, Stephens N, Grim A, Barrett AJ. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant. 2010;16:1549\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2886_CR22","doi-asserted-by":"publisher","first-page":"e13086","DOI":"10.1111\/tid.13086","volume":"21","author":"R Yamazaki","year":"2019","unstructured":"Yamazaki R, Kato J, Koda Y, Sakurai M, Tozawa K, Okayama M, et al. Impact of immunoglobulin G2 subclass level on late-onset bacterial infection after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2019;21:e13086.","journal-title":"Transpl Infect Dis"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02886-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02886-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02886-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:49:04Z","timestamp":1619484544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02886-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02886-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no potential competing conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}